FISPB
NBIX icon

Fideuram - Intesa Sanpaolo Private Banking’s Neurocrine Biosciences NBIX Stock Holding History

Fideuram - Intesa Sanpaolo Private Banking’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Buy
25,658
+13,015
+103% +$1.93M 0.13% 166
2026
Q1 		$1.67M Sell
12,643
-511
-4% -$67.8K 0.06% 242
2025
Q4 		$1.87M Buy
+13,154
New +$1.91M 0.07% 228

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking's NBIX Position: Q2 2026 in Review

Fideuram - Intesa Sanpaolo Private Banking increased its Neurocrine Biosciences (NBIX) stake by 103% in Q2 2026, buying an estimated $1.93M and bringing the position to 25,658 shares worth $4.32M. The position accounts for 0.13% of the portfolio, ranked #166.

Fideuram - Intesa Sanpaolo Private Banking first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Fideuram - Intesa Sanpaolo Private Banking held 25,658 shares of Neurocrine Biosciences worth $4.32M as of Q2 2026.
  • Fideuram - Intesa Sanpaolo Private Banking bought 13,015 Neurocrine Biosciences shares in Q2 2026, an estimated $1.93M.
  • Neurocrine Biosciences made up 0.13% of Fideuram - Intesa Sanpaolo Private Banking's portfolio in Q2 2026, its #166 holding.
  • Fideuram - Intesa Sanpaolo Private Banking first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Fideuram - Intesa Sanpaolo Private Banking's 13F filing for Q2 2026, filed 23 Jul 2026.